Achieve Life Sciences, Inc

Newest shelf

$300.0M

S-3 of 2026-01-23. 1 prospectus supplement filed under it since. S-3 ↗

At the market

$150.0M

Jefferies, agreement of 2026-08-14. No at-the-market sales statement read from a 10-Q or 10-K. 424B5 ↗

Warrants

The 10-Q filed 2026-08-11 is not read yet.

Cash

15.9 quarters

$187.3M on 2026-06-30 ÷ $11.8M a quarter of operating cash used, the average of four quarters. 10-Q ↗